Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2021-03-22 Regulatory Filings
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-03-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing an agreement for in vivo testing of a pharmaceutical asset (iCo-019) against SARS-CoV-2. It contains forward-looking statements about the study and research activities but does not include any financial data, regulatory filings, or detailed financial reports. There is no indication of financial results, management changes, voting results, or other regulatory filings. The content is primarily an update on a research and development activity, typical of a corporate announcement or news release. This type of document does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filings (RNS) because it is a general regulatory announcement and does not fit any other specific category.
2021-03-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the exercise of warrants by shareholders, resulting in proceeds to the company. It discusses capital raised through warrant exercises and includes forward-looking statements about the use of funds. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The content focuses on financing activity and capital structure changes. The document length is short (3506 characters) and it is clearly an announcement rather than a detailed report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-03-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from iCo Therapeutics Inc. stating that the company is unaware of any material change that would explain recent market activity. It is a short announcement primarily addressing regulatory concerns from IIROC and does not contain any financial data, detailed report, or management discussion. It also includes forward-looking statements disclaimers typical of press releases. The document length is only 3077 characters, which is quite short and does not contain any financial statements or substantive analysis. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. It is essentially a regulatory announcement responding to market activity inquiries. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-02-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the company's proposal to re-price warrants, which relates to changes in the terms of existing financial instruments. It discusses the amendment of exercise prices for warrants issued in previous private placements and mentions the company's strategic initiatives and potential capital raising through warrant exercises. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is not an earnings release, annual or interim report, or any form of audit or management report. It is an update on capital structure and financing terms, specifically about warrant re-pricing, which fits the Capital/Financing Update category. The document length is under 5,000 characters and is a standalone announcement, not a report publication notice or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-01-12 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a joint development agreement between iCo Therapeutics and Skymount Medical regarding a pharmaceutical product. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed investor presentation. The content is primarily a business update about a collaboration and funding commitment, typical of a capital or financing update. The document length is about 4940 characters, which is short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-12-31 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.